Published on March 30, 2010 at 7:11 AM
StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. (Nasdaq:MRNA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/MRNA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
MDRNA Inc. (MRNA) is a biotechnology company focused on the discovery, development and commercialization of pharmaceuticals based on RNA interference (RNAi). Over the past decade, the Company has developed substantial capabilities in molecular biology, cellular biology, amino acid chemistry, peptide chemistry, pharmacology and bioinformatics, which MRNA is applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled the Company to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology.
Message Board Search for MRNA: http://www.boardcentral.com/boards/MRNA
In the report, the analyst notes:
"The Company recently announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/701,397 covering methods for the delivery of siRNAs as well as a broad array of compounds with pharmacological activity. The patent identifies and protects peptides that were discovered using the Company's proprietary Trp Cage Phage Display Library and describes targeting peptides that demonstrate high binding affinity to, and internalization by, hepatocellular carcinoma cells.
"MRNA announced last week that it acquired the intellectual property rights for bridged nucleic acids (BNAs) from Valeant Pharmaceuticals North America, broadening the Company's RNAi-drug discovery platform."
SOURCE StockPreacher.com